View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 15, 2018updated 12 Jul 2022 1:13pm

TLC doses first patients in Phase I/II study of TLC590

Taiwan Liposome Company (TLC) has dosed the first patients in a Phase I/II trial to investigate TLC590 in comparison with free, non-liposomal ropivacaine when given as a single infiltrative local administration for the treatment of adult patients following inguinal hernia repair surgery.

Taiwan Liposome Company (TLC) has dosed the first patients in a Phase I/II trial to investigate TLC590 in comparison with free, non-liposomal ropivacaine when given as a single infiltrative local administration for the treatment of adult patients following inguinal hernia repair surgery.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The randomised, double-blind, comparator-controlled, dose-escalation trial has so far included 12 patients, three of whom were dosed.

The trial aims to analyse the safety, tolerability, pharmacokinetics (PK), dose-exposure relationships, and analgesic efficacy of dose escalation of TLC590 compared to free, non-liposomal ropivacaine.

It is currently being carried out in the US with plans to enrol around 64 patients who will be followed up for 30 days after surgery and dosing.

“The randomised, double-blind, comparator-controlled, dose-escalation trial has so far included 12 patients, three of whom were dosed.”

Taiwan Liposome Company founder, chairman and CEO Dr Keelung Hong said: “TLC590 is formulated with our proprietary BioSeizer liposome technology, which has a dense multilamellar structure capable of providing high-concentration drug loading and continuous release of ropivacaine,.

“Our preclinical studies have shown TLC590 to display statistically significant analgesic efficacy compared to liposomal bupivacaine, and we are excited to have begun dosing patients in our first-in-human clinical trial to demonstrate TLC590 as a potentially best-in-class drug for postsurgical pain management that may serve as a safe, non-opioid solution to the opioid epidemic.”

Ropivacaine, a common local anesthetic drug in the amino amide group that was developed after bupivacaine, was previously demonstrated to have less cardiovascular and central nervous system toxicity than bupivacaine.

Bupivacaine is currently being used in the US and has demonstrated significant efficacy up to 24 hours post-surgery, but showed minimal to no efficacy between 24 and 72 hours after administration.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena